Illumina, Inc. vs Tidewater Inc — how do they compare? Illumina, Inc. trades at $273.58 (market cap $39.95B), while Tidewater Inc trades at $85.29 (market cap $4.21B). The key difference: Illumina, Inc. is far larger — about 9.5× Tidewater Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Tidewater Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Tidewater Inc for 25 Days on average.
| ILMN | TDW | |
|---|---|---|
Market Cap | $39.95B | $4.21B |
Volume | 3,169,503 | 590,005 |
Sector | Health | Energy |
52-Week High | $293.69 | $100.61 |
52-Week Low | $91.00 | $47.29 |
Typical Hold Time | 83 Days | 25 Days |
Enterprise Value | $41.31B | $4.25B |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Tidewater (TDW) trades at $83.40, up 1.62% on the day, with a bullish technical signal driven by moving averages. Recent earnings showed a Q2 2026 beat but misses in Q1 and Q2 relative to expectations, while the company completed the Wilson Sons Ultratug acquisition in August 2026, signaling growth initiatives. Key financials include a P/E of 17.18 and net income margin of 18.34% for 2025, though 2026 projections indicate lower revenue and profitability.
The outlook is mixed, with analyst consensus leaning toward a buy rating and a price target of $105.50 offering upside potential, but risks include earnings volatility, competitive pressures in the energy sector, and macroeconomic headwinds affecting day rates and utilization.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →